We’re a biotechnology company on a mission to develop therapies that will get patients with a heart attack to the hospital with open coronary arteries. We focus on developing pre-hospital therapies, because early action is crucial to preserve heart muscle.
The longer a coronary artery is closed, the more severe the damage to the heart. Starting treatment before patients reach the hospital, significantly improves the chances of a positive outcome.
We’re developing zalunfiban; a prompt, potent, and predictable medication designed for treating patients with a heart attack before they reach the hospital. Zalunfiban has the potential to fulfil a significant unmet medical need in the pre-hospital phase of heart attack care.
We’re currently running the CeleBrate trial: a pivotal Phase 3 prospective, blinded, randomized, placebo-controlled, international, multicenter, study designed to assess the safety and efficacy of a single subcutaneous injection of zalunfiban in patients with ST-segment elevation myocardial infarction in the pre-hospital setting.
Company Details
- Employees
- 5
- Founded
- -
- Address
- 1155 Camino Del Mar, Del Mar,california 92014,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.celecor.com
- HQ
- Del Mar, California
Celecor Therapeutics Questions
Celecor Therapeutics's website is https://www.celecor.com
Celecor Therapeutics's LinkedIn profile is https://www.linkedin.com/company/celecor
Celecor Therapeutics has
5 employees.
View email and phone details for 5
employees at Celecor Therapeutics.
Celecor Therapeutics's industry is
Biotechnology Research
Celecor Therapeutics's top competitors are
Pictorlabs Inc,
Viatris,
Amgen,
Diagram | Your Expert In Cardiovascular Research,
Human Longevity, Inc.,
Cra+ (Cra Plus),
Xenotherapeutics,
Anewcro, Llc.,
Altani360,
Illumina.
Celecor Therapeutics's categories are Biotechnology Research
Celecor Therapeutics's founding year is 2017
